Waiting For Biosimilars: From Manufacturing To Litigation, Stakeholders Prepare For U.S. Market
Executive Summary
Leading players in the biosimilars realm discuss possible roadblocks to development, the battle over naming and substitution, and strategies to avoid the patent litigation dance.
You may also be interested in...
Celltrion’s Remicade Biosimilar Takes U.S. Regulatory Shortcuts
After just one year of working with the U.S FDA, the South Korean company is positioning itself to launch its first monoclonal antibody biosimilar in the U.S. market.
GPhA And Actavis Divorcing: Biosimilars Behind The Rift
Actavis, the hybridizing generics giant that once helped keep GPhA together, now appears to be splitting off in a dispute over state substitution strategy.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.